Oct4 Cell-Autonomously Promotes Primitive Endoderm Development in the Mouse Blastocyst  by Frum, Tristan et al.
Developmental Cell
ArticleOct4 Cell-Autonomously Promotes
Primitive Endoderm Development
in the Mouse Blastocyst
Tristan Frum,1 Michael A. Halbisen,1 Chaoyang Wang,2 Hossein Amiri,1 Paul Robson,2,3 and Amy Ralston1,*
1Department of Molecular, Cell, and Developmental Biology, University of California, Santa Cruz, Santa Cruz, CA 95064, USA
2Developmental Cellomics Laboratory, Genome Institute of Singapore, Singapore 138672, Singapore
3Department of Biological Sciences, National University of Singapore, Singapore 117543, Singapore
*Correspondence: ralston@biology.ucsc.edu
http://dx.doi.org/10.1016/j.devcel.2013.05.004SUMMARY
In embryonic stem (ES) cells and in early mouse
embryos, the transcription factor Oct4 is an essential
regulator of pluripotency. Oct4 transcriptional tar-
gets have been described in ES cell lines; however,
the molecular mechanisms by which Oct4 regulates
establishment of pluripotency in the epiblast (EPI)
have not been fully elucidated. Here, we show that
neither maternal nor zygotic Oct4 is required for the
formation of EPI cells in the blastocyst. Rather,
Oct4 is first required for development of the primitive
endoderm (PE), an extraembryonic lineage. EPI cells
promote PE fate in neighboring cells by secreting
Fgf4, and Oct4 is required for expression of Fgf4,
but we show that Oct4 promotes PE development
cell-autonomously, downstream of Fgf4 and Mapk.
Finally, we show that Oct4 is required for the expres-
sion of multiple EPI and PE genes as well as multiple
metabolic pathways essential for the continued
growth of the preimplantation embryo.
INTRODUCTION
Since embryonic stem (ES) cells are derived from the blastocyst,
understanding how cell fates are established during develop-
ment provides key lessons for ES cell biology. During formation
of the mouse blastocyst, cell fates are selected by regulated cell
fate decisions. First, the inner cell mass (ICM) is segregated from
the differentiating trophectoderm (TE; future placenta) around
embryonic day (E) 3.0. Subsequently, the ICM is subdivided
into the pluripotent epiblast (EPI) and the primitive endoderm
(PE; future yolk sac) around E3.75. Recent work has revealed
that EPI cells help induce the formation of PE cells by secreting
Fgf4, which then induces the expression of PE genes via Mapk
(Chazaud et al., 2006; Guo et al., 2010; Kang et al., 2013; Nichols
et al., 2009; Yamanaka et al., 2010). Thus, pluripotency genes,
such as Nanog, induce PE differentiation non-cell-autonomously
(Frankenberg et al., 2011; Messerschmidt and Kemler, 2010).
Simultaneously, Nanog also represses expression of the PE
gene Gata6 cell-autonomously within EPI cells (Frankenberg610 Developmental Cell 25, 610–622, June 24, 2013 ª2013 Elsevier Iet al., 2011). Together, these mechanisms produce a ‘‘salt and
pepper’’ distribution of EPI and PE cells within the ICM at
E3.75. Prior to this time point (E3.5), additional PE genes
(Sox17 and Pdgfra) are expressed in a subset of ICM cells and
by E3.75, Gata6 is coexpressed with Sox17, Pdgfra, and
Gata4 in the PE (Artus et al., 2011; Niakan et al., 2010; Plusa
et al., 2008). By the time of implantation, EPI and PE cells will
have sorted into distinct groups of cells, and Sox7 is then
expressed in PE cells by E4.0 (Artus et al., 2011).
In both the embryo and in ES cells, Oct4 is widely appreciated
as an essential pluripotency factor. ES cells cannot be derived
from Oct4 null embryos, owing to conversion of ICM to TE fate
(Nichols et al., 1998). However, not all ICM cells acquire TE
gene expression in Oct4 null embryos (Ralston et al., 2010),
suggesting that Oct4 may promote pluripotency in vivo by a
mechanism distinct from repression of TE. Alternatively,
maternal Oct4 could partially compensate for the loss of zygotic
Oct4 during cell fate specification in the blastocyst (Foygel
et al., 2008). Ultimately, the mechanisms by which Oct4 regu-
lates cell fate specification during blastocyst formation are
unclear, as are the Oct4-dependent genes.
Here, we show that neither maternal nor zygotic Oct4 is
required for the initial expression of Nanog or Sox2 or for forma-
tion of the blastocyst. Rather, zygotic Oct4 is required for PE
cell fate. Surprisingly, the mechanism by which Oct4 promotes
PE fate differs from the mechanism by which Nanog promotes
PE fate. While Nanog induces PE fate non-cell-autonomously,
upstream of Fgf4 (Frankenberg et al., 2011; Messerschmidt
and Kemler, 2010), we show that Oct4 promotes PE gene
expression cell-autonomously and is required for Fgf4/Mapk to
activate expression of PE genes. Finally, by transcriptome anal-
ysis, we identify pluripotency genes whose expression is depen-
dent on Oct4 in the blastocyst, including Esrrb, Klf2, and
Zscan10. In addition, we present evidence that the develop-
mental arrest ofOct4 embryos is associatedwith a failure to tran-
scriptionally activate multiple energetic metabolism pathways
rather than apoptosis.
RESULTS
Oct4 Is Required toMaintain Expression ofGata6 andPE
Cell Number
Our prior work indicated that Oct4 is required to repress the TE
genes Cdx2 and Gata3 in a subset of ICM cells (Ralston et al.,nc.
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Figure 1. Zygotic Oct4 Is Required for Maintenance of Gata6 Expression
(A–C) Gata6 and Nanog immunostaining inOct4 null and nonmutant embryos at indicated stages (white arrowhead, unlabeled cells; dotted line, ICM; bar, 20 mm).
(D) Average numbers of inside and outside cells in Oct4 null and nonmutant embryos.
(E) Average proportions of inside and outside cells in Oct4 null and nonmutant embryos examined in (D)–(I).
(F–H) Average numbers of ICM cells labeled by Nanog, Gata6, or neither.
(I) Average proportions of inside cells labeled with Nanog, Gata6, or neither.
(J) Average numbers of TUNEL-positive inside and outside cells in Oct4 null and nonmutant embryos.
For (D)–(J), n is the number of embryos examined and error bars represent SD. p, p value.
See also Figure S1.
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Oct4 Promotes Endodermal Differentiation In Vivo2010), but it was not clear whether acquisition of TE fate disrup-
ted EPI or PE fate or both.We therefore examined EPI and PE cell
fate specification (defined on the basis of Nanog and Gata6
expression) in litters collected from Oct4 zygotic null heterozy-
gous intercrosses at stages when Nanog and Gata6 adopt a
mutually exclusive expression pattern in EPI and PE cells
(E3.75) and then sort into morphologically discrete groups
(E4.0, E4.25). Nonmutant embryos possessed expected average
cell numbers (Figure S1A available online), indicating that ourDevelstaging scheme can be directly compared with published ana-
lyses of preimplantation development. At E3.75, the expression
of Gata6 and Nanog appeared similar between Oct4 null
embryos and nonmutant littermates (Figure 1A). However, start-
ing at E4.0, a decline in Gata6 expression level was apparent in
Oct4 null embryos. In nonmutant embryos at E4.0, Gata6-
positive and Nanog-positive cells were localized to prospective
PE and EPI regions, but in Oct4 null embryos, Gata6 was weakly
detectable in only a few cells (Figure 1B). In nonmutant embryosopmental Cell 25, 610–622, June 24, 2013 ª2013 Elsevier Inc. 611
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Oct4 Promotes Endodermal Differentiation In Vivoat E4.25, Gata6-positive and Nanog-positive cells had further
sorted into distinct regions within the ICM. In Oct4 null embryos,
which had collapsed, Gata6 was no longer detectable and
Nanog-positive cells had not sorted into a discrete EPI layer
but were intermingled with unlabeled cells (Figure 1C). We
conclude that zygotic Oct4 is not required for expression of
Nanog in EPI cells, consistent with prior observations (Chambers
et al., 2003), and that Oct4 is required to maintain expression of
Gata6 in PE cells after E3.75.
Oct4 null embryos were previously reported to arrest around
E4.5 (Nichols et al., 1998). Consistent with this, we noted that
the average numbers of inside and outside cells were similar
between Oct4 null and nonmutant embryos at E3.75 and E4.0,
but both were significantly reduced in Oct4 null embryos by
E4.25 (p < 0.001; Figure 1D), indicating defects in both ICM
and TE development. At E4.25, the inside cell population was
disproportionately smaller in Oct4 null embryos than in nonmu-
tant embryos (p < 0.001; Figure 1E). We therefore asked whether
this was due to a loss of either EPI or PE cells over the course of
preimplantation development. By counting Nanog-positive,
Gata6-positive, and unlabeled (Gata6-negative/Nanog-nega-
tive) cells in Oct4 null and nonmutant littermates, we determined
that both the average number and the proportion of Gata6-pos-
itive cells progressively decreased inOct4 null embryos over the
course of preimplantation development (Figures 1G and 1I).
Comparing Oct4 null embryos at E3.75 and E4.25, the decrease
in the average number of Gata6-positive cells was significant
(p = 0.002), consistent with either a loss of PE cells or their con-
version to EPI cell fate. However, we detected an increase in
both the average number and the proportion of unlabeled cells
in Oct4 null embryos from E3.75 to E4.25 (Figures 1H and 1I),
which differed significantly from nonmutant embryos at all time
points (Figure 1I). By contrast, the average number of Nanog-
positive cells did not differ significantly between Oct4 null and
nonmutant embryos until the latest time point, when the average
number of Nanog-positive cells was significantly lower in Oct4
null embryos (p = 0.009; Figure 1F), suggesting that PE cells
do not acquire EPI cell fate in Oct4 null embryos. Since the pro-
portion of Nanog-positive cells was significantly greater in Oct4
null ICMs than in nonmutant ICMs (p < 0.001; Figure 1I), this sug-
gests that PE cells cease to proliferate or die between E4.0 and
E4.25. By TUNEL assay, we compared the number of apoptotic
cells betweenOct4 null and nonmutant littermates and observed
no significant difference in the average number of TUNEL-posi-
tive cells in Oct4 null blastocysts at E4.0 or E4.25 compared to
nonmutants (Figure 1J; Figure S1B). These results indicate that
Oct4 is required to maintain expression of Gata6 in the fully
expanded blastocyst and to promote proliferation of EPI, PE,
and TE cells prior to implantation.
Oct4 Is Required for Expression of Multiple PE Fate
Markers
Development of the PE lineage is characterized by the sequential
activation of multiple genes. Subsequent to Gata6 expression,
Sox17 and Pdgfra are detected starting at E3.5, followed by
expression of Gata4, which is initiated at E3.75, and Sox7, which
is initiated at E4.0 (Artus et al., 2011; Niakan et al., 2010; Plusa
et al., 2008). Interestingly, neither Sox17 nor Pdgfra was detect-
able above background inOct4 null embryos at E3.5 or later (Fig-612 Developmental Cell 25, 610–622, June 24, 2013 ª2013 Elsevier Iures 2A and 2B; Figure S2). Low levels of Gata4 were detectable
inOct4 null embryos at E3.75, but Sox7was not detected inOct4
null embryos at E4.0 (Figures 2C and 2D). These observations
indicate that Oct4 promotes expression of some PE genes
(Sox17 and Pdgfra) as early as E3.5 in addition to its role promot-
ing other PE genes (Gata6, Gata4, and Sox7) by E3.75–E4.0.
Thus, Oct4 is required for initial development of PE cell fate
and not simply its maintenance.
We next asked whether PE development is disrupted in Oct4
null embryos because the ICM differentiates into trophoblast
(Nichols et al., 1998). We previously showed that Oct4 represses
expression of Cdx2 in the ICM (Ralston et al., 2010). If TE fate dis-
rupts PE fate specification, then we expected to detect elevated
Cdx2 in all PE cells of Oct4 null embryos at E4.0. To identify pre-
sumptive PE cells in the Oct4 null embryos, we used Nanog to
label the EPI cells, leaving the presumptive PE cells unlabeled.
If acquisition of Cdx2 disrupts PE gene expression, then we
would expect to observe an inverse correlation between Nanog
and Cdx2 expression inOct4 null embryos. However, we did not
observe an inverse correlation between Nanog and Cdx2
expression in Oct4 null embryos. Rather, Cdx2 was ectopically
expressed in both EPI (Nanog-positive) and PE (Nanog-negative)
populations with equal frequency (Figures 2E and 2F; p = 0.35,
Fisher’s test) in Oct4 null embryos. Moreover, Cdx2 was only
detected in about half ofOct4 null PE cells (Figure 2F). Therefore,
acquisition of Cdx2 is not correlated with loss of PE gene
expression in Oct4 null embryos. We conclude that Oct4 pro-
motes expression of PE genes through a Cdx2-independent
mechanism.
Maternal Oct4 Is Dispensable for Development
We next asked whether the initial expression of Gata6 and
Nanog depends on maternal Oct4, since Oct4 is present in
oocytes (Rosner et al., 1990) and small interfering RNA knock-
down of maternal (m) and zygotic (z) Oct4 leads to develop-
mental arrest prior to the blastocyst stage (Foygel et al., 2008).
We used the female germline-expressed Zp3-Cre (de Vries
et al., 2000) to delete a conditional allele of Oct4 during oogen-
esis (Figure 3A). By quantitative PCR (qPCR), we verified that
Oct4 transcript levels were reduced to undetectable levels in
oocytes from Oct4 germline-deleted females (Figure 3B). When
Oct4 germline-deleted females were mated to wild-type males,
live pups lacking m Oct4 were born (24/24 pups genotyped),
and litters from these crosses were not significantly smaller
than control crosses (10.3 ± 1.5 and 7.0 ± 0.8 pups/litter, respec-
tively). Since only half of the Oct4 m null pups had inherited the
Zp3-Cre transgene (13/24 pups), Oct4 deletion must have
occurred during oogenesis. We conclude that m Oct4 is not
required for fetal development.
We next examined whether z Oct4 compensates for loss of m
Oct4 by generating Oct4 mz null embryos (Figure 3A). At E3.75,
Oct4 mz null embryos had formed a blastocyst structure, and
PCR genotyping confirmed that Oct4 mz null blastocysts were
detected within litters at the expected frequency (16 m null:
12 mz null; Figure 3C). We observed no significant difference in
the average numbers of inside and outside cells in Oct4 z
null, Oct4 m null, and wild-type blastocysts (Figure 3C). More-
over, Gata6 and Nanog were both still detectable in Oct4 mz
null embryos (Figure 3D) and the numbers of Gata6 andnc.
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Figure 2. Expression of PE Genes Is Disrupted in Oct4 Null Embryos and Is Not Due to Ectopic Expression of Cdx2
(A–D) Pdgfra, Sox17, Gata4, and Sox7 immunostaining in Oct4 null and nonmutant embryos at indicated stages. White bar, 20 mm.
(E) Nanog and Cdx2 immunostaining in Oct4 null embryo and nonmutant embryos at E4.0. Dotted line, ICM; arrow, a Cdx2-negative PE cell; white bar, 20 mm.
(F) Average number ofOct4 null ICM cells expressing Cdx2 or Nanog at E4.0 (n = 10 embryos). Cdx2 was detected in only about half of PE (Nanog-negative) cells,
indicating that ectopic Cdx2 cannot account for the loss of PE gene expression in all PE cells in Oct4 null embryos. By comparison, Cdx2 is never detected in
nonmutant ICM cells at E4.0 (Strumpf et al., 2005; Ralston and Rossant, 2008; Ralston et al., 2010).
See also Figure S2.
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Oct4 Promotes Endodermal Differentiation In VivoNanog-expressing cells did not differ significantly between Oct4
mz null and z null embryos (Figure 3E). We conclude that both
blastocyst formation and the initial regulation of Gata6 and
Nanog expression are Oct4 independent. In addition, we deter-
mined that expression of Sox2, another EPI marker (Aksoy et al.,
2013; Guo et al., 2010), was unaffected in Oct4mz null embryos
(Figure S3). Thus, neither m nor zOct4 is required for formation of
the blastocyst or for the initial segregation of EPI and PE cell
types.
Oct4 Is Not Required for Mapk-Dependent Regulation
of Nanog
Our results showed that neither m nor z Oct4 is required for the
salt-and-pepper regulation of Nanog and Gata6 in the ICM. The
salt-and-pepper regulation of Nanog and Gata6 is known to
depend on Fgf4/Mapk signaling, which represses Nanog and
promotes Gata6 in PE cells (Nichols et al., 2009; Yamanaka
et al., 2010). Since this salt and peppering can occur in the
absence of Oct4, we hypothesized that Fgf/Mapk signaling is
active in Oct4 null embryos. To test this hypothesis, we treated
Oct4 null embryos and nonmutant embryos with inhibitors of
Fgfr/Mapk from E2.75 to E4.0 (Yamanaka et al., 2010), with the
expectation that this treatment should elevate Nanog andDevelrepress Gata6 expression if Fgfr/Mapk signaling is intact in
Oct4 null embryos. In nonmutant embryos treated with Fgfr/
Mapk inhibitors, Nanog was ectopically expressed and Gata6
repressed throughout the ICM as expected (Figures 4A and
4B). In Oct4 null embryos treated with Fgfr/Mapk inhibitors,
Nanog was also ectopically expressed throughout the ICM
(Figures 4A–4C). Thus, Fgfr/Mapk signaling regulates Nanog
expression in PE cells in an Oct4-independent manner.
Surprisingly, Fgfr/Mapk inhibitors did not repress Gata6
expression in Oct4 null embryos as they did in nonmutant em-
bryos. In fact, both the intensity of Gata6 immunostaining and
the average number of Gata6-positive cells appeared elevated
in Oct4 null embryos treated with Fgfr/Mapk inhibitors (Figures
4A and 4C). This was unexpected, because ectopic Nanog
should have repressed Gata6 (Frankenberg et al., 2011; Yama-
naka et al., 2010) in the PE cells of inhibitor-treated Oct4 null
embryos. Our results therefore suggest that Oct4 participates
in Nanog-mediated repression of Gata6. These results are
consistent with the proposal that Fgfr/Mapk signaling promotes
Gata6 in PE cells by relieving Nanog-mediated repression
of Gata6 (Frankenberg et al., 2011). Moreover, we observed
Gata6 expression in Oct4 null embryos whether the inhibitor
treatment was started at E2.5 or E2.75 (Figures S4A and S4B),opmental Cell 25, 610–622, June 24, 2013 ª2013 Elsevier Inc. 613
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Figure 3. Repression of Nanog and Expression of Gata6 Is Independent of Maternal Oct4
(A) Breeding strategy for generating m and mz null Oct4 offspring. del, deleted; fl, floxed.
(B) qPCR analysis of averageOct4 transcript levels in wild-type andOct4maternal null oocytes (n = 3 pools of 10 oocytes per genotype). Error bars represent SD.
(C) Average numbers of inside and outside cells in blastocysts of indicated genotypes. Error bars represent SD.
(D) Gata6 and Nanog immunostaining in Oct4 m null and Oct4 mz null embryos (bar, 20 mm).
(E) Average numbers of Gata6 or Nanog-positive cells in blastocysts of indicated genotypes. Error bars represent SD.
See also Figure S3.
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Oct4 Promotes Endodermal Differentiation In Vivoconsistent with the finding that early Gata6 expression is Fgf4
independent (Kang et al., 2013). By contrast, other PE genes
(Sox17 and Sox7) were not ectopically expressed in inhibitor-
treated Oct4 null embryos (Figures S4C and S4D). Rather,
Sox17 and Sox7 were repressed in both Oct4 null and nonmu-
tant embryos following treatment with Fgfr/Mapk inhibitors.
Together, these data suggest that Oct4 is not required for
Fgfr/Mapk-dependent repression of Nanog but is required for
Nanog-dependent repression of Gata6 in the ICM.
Oct4 Is Required for Fgf4-Induced Expression of
Multiple PE Genes
Our results suggested that Fgfr/Mapk signaling actively
represses Nanog in PE cells of Oct4 null embryos, in spite of
the fact that Fgf4 messenger RNA (mRNA) levels are lower in
Oct4 null embryos (Nichols et al., 1998). However, it was unclear
whether the reduced level of Fgf4 mRNA expression in Oct4
embryos could explain the loss of PE genes, such as Sox17,
Sox7, and eventually Gata6. We next tested whether PE gene
expression could be rescued in Oct4 null embryos by treatment
with exogenous Fgf4. Expression of PE genes is induced in wild-
type, Fgf4 null, and Nanog null embryos cultured in exogenous
Fgf4 and heparin (Fgf4/Hep) (Frankenberg et al., 2011; Kang
et al., 2013). In nonmutant embryos, Fgf4/Hep treatment from614 Developmental Cell 25, 610–622, June 24, 2013 ª2013 Elsevier IE2.75 to E4.5 led to ectopic expression of Gata6 and Sox17
throughout the ICM (Figures 4D, 4E, 4G, and 4H), as expected.
However, in Oct4 null embryos, Fgf4/Hep treatment failed to
expand the expression domains of Gata6 or Sox17 (Figures
4D, 4E, 4G, and 4H). In Oct4 null embryos, Fgf4/Hep treatment
induced Sox17 at low levels in one or two ICM cells of some em-
bryos (Figures 4E and 4H), but this level of PE gene expression
was not adequate to facilitate outgrowth of PE cells in cultured
Oct4 null blastocysts (Figure S4E). Notably, Fgf4/Hep treatment
was able to induce similar low levels of Sox17 inOct4mz null and
Oct4 z null embryos (Figure 4J). Thus moderate levels of Sox17
expression can be induced by high levels of Fgf4/Hep in the
complete absence of Oct4, but Oct4 is required for robust acti-
vation of PE genes in response to exogenous Fgf4. These
results are consistent with Oct4 acting downstream of Fgf4,
but indicate that exogenous Fgf4 can induce modest PE gene
expression in parallel to the Oct4-dependent pathway that nor-
mally activates expression of PE genes.
Finally, we examined expression of Nanog in Fgf4/Hep-treated
Oct4 null embryos. In nonmutant embryos, Fgf4/Hep treatment
abolished expression of Nanog (Figures 4F and 4I), as expected.
However, in Oct4 null embryos, the proportion of Nanog-
expressing cells was unchanged by Fgf4/Hep treatment. These
observations indicate that Oct4 is required for exogenous Fgf4nc.
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Figure 4. Oct4 Is Required for Fgf/Mapk-Dependent Expression of PE Genes
(A) Nanog and Gata6 immunostaining in Oct4 null embryos cultured from E2.75 to E4.25 in control medium or medium containing Fgfr/Mapk inhibitors.
(B and C) Average proportions of inside cells expressing Nanog or Gata6 in Oct4 null and nonmutant embryos following culture in control medium or Fgfr/Mapk
inhibitors.
(D–F) Gata6, Sox17, and Nanog immunostaining in Oct4 null embryos and wild-type embryos cultured from E2.75 to E4.5 in Fgf4/Hep.
(G–I) Average proportions of ICM cells expressing Gata6, Sox17, or Nanog inOct4 null and wild-type embryos cultured from E2.75 to E4.5 in Fgf4/Hep or control
medium.
(J) Average proportions ofOct4 z null or mz null ICM cells in which Sox17 or Nanog is weakly detected after culturing in Fgf4/Hep or control medium E2.75–E4.5.
Error bars represent SD. See also Figure S4.
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Oct4 Promotes Endodermal Differentiation In Vivoto repress Nanog in EPI cells, which could explain the failure of
exogenousFgf4 to induceGata6expression inOct4null EPI cells.
However, in Fgf4-treatedOct4null PEcells,which do not express
Nanog, Oct4 is required for expression of Gata6 and Sox17.DevelOct4 Is Required Cell-Autonomously for PE Gene
Expression
Our observations that Oct4 is required for ICM cells to respond
to exogenous Fgf4, along with the observation that Oct4 isopmental Cell 25, 610–622, June 24, 2013 ª2013 Elsevier Inc. 615
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Figure 5. Oct4 Cell-Autonomously Promotes Expression of PE Genes
(A) Schematic of method used to generate chimeric embryos.
(B) Comparable contribution of ES cells to Oct4 null or nonmutant embryo hosts.
(C) Sox17 and GFP in control and Oct4 null chimeras.
(D) Sox7 and GFP in control and Oct4 null chimeras. Note the presence of a rare Sox7-positive cell in the Oct4 null chimera.
(E and F) Average proportions of ICM cells in which Sox17 or Sox7 are detected in chimeras generated from Oct4 null or nonmutant host embryos.
Error bars represent SD. See also Figure S5.
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gested that Oct4 acts cell-autonomously in PE cells. To test
whether Oct4 is required cell-autonomously in PE cells, we
generated chimeric embryos by aggregating fluorescently
labeled wild-type ES cells with Oct4 null or nonmutant host em-
bryos at the precompacted eight-cell stage (E2.5), which leads to
almost entirely ES-cell-derived fetuses (Poueymirou et al., 2007),
and examined PE rescue in chimeric embryos at E4.25 (Fig-
ure 5A). We predicted that if Oct4 were required cell-autono-
mously in PE cells, then wild-type ES cells would fail to rescue
PE gene expression in Oct4 null chimeras. We first established
that the contribution of ES cells to Oct4 null and nonmutant
host embryos was equivalent (Figure 5B). Next, we determined
that Sox17 and Sox7 were each strongly induced by ES cells
in nonmutant host embryos (Figures 5C–5F). However, ES cells
failed to strongly induce either Sox17 or Sox7 in Oct4 null chi-
meras (Figures 5C–5F). In someOct4 null chimeras, we detected
one or two cells expressing Sox17 or Sox7 (6/10 and 1/6 chi-
meras, respectively) (Figures 5D–5F). Importantly, the low level
of Sox17 or Sox7 expression was not correlated with the number
of ES cells present in the chimera (Figure S5A), nor was the low616 Developmental Cell 25, 610–622, June 24, 2013 ª2013 Elsevier Ilevel of Sox17 expression dependent on maternal Oct4, since
Sox17 was also induced inefficiently in Oct4 mz null embryos
complemented with wild-type ES cells (Figure 5SB). The low
levels of PE gene expression inOct4 null chimeras are consistent
with the notion that Fgf4 can induce modest PE gene expression
in parallel to the Oct4-dependent pathway. However, full activa-
tion of PE gene expression requires Oct4 cell-autonomously,
since wild-type ES cells failed to rescue the Oct4 null PE
phenotype.
Oct4Regulates Expression ofMultiple PE andEPIGenes
To gain more comprehensive insight into the role of Oct4 in
blastocyst formation, we compared the transcriptomes of
Oct4 null and wild-type embryos by RNA sequencing (RNA-
seq) individual whole embryos at time points before, during,
and after EPI/PE specification (E2.5, E3.75, and E4.5). We first
evaluated differences in global gene expression patterns be-
tween genotypes at each stage by multidimensional scaling,
which showed separation between genotypes for all individuals
at each embryonic stage; however, embryos showed tighter
clustering within genotypes at E4.5 (Figure 6A), the stage atnc.
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Accordingly, we were able to resolve greater numbers of statis-
tically significant Oct4-dependent genes prior to E4.5 (Fig-
ure 6B; Table S1). Notably, Oct4 was significantly lower in
Oct4 null embryos at all stages, as were the levels of Sox17,
Pdgfra, and Gata4, consistent with our immunofluorescence an-
alyses, and other PE genes such as Sparc, Lama1, Lamb1, and
Lamc1 (Miner et al., 2004; Niakan et al., 2010). We also
observed significantly lower levels of the pluripotency genes
Esrrb, Klf2, and Zscan10 (Ivanova et al., 2006; Jiang et al.,
2008; Martello et al., 2012; Wang et al., 2007; Zhang et al.,
2006) in Oct4 null embryos. By contrast, expression levels of
TE genes Cdx2, Krt8, and Gata3 were not significantly upregu-
lated in Oct4 null embryos at any stage, although Eomes was
significantly upregulated in Oct4 null embryos at E2.5. These
observations suggest that our statistical threshold restricted
the lists of Oct4-dependent genes to genes exhibiting strong
and reproducible expression differences between whole Oct4
null and wild-type embryos. In addition, since whole embryos
were sequenced, we were unable to discriminate gene expres-
sion changes in a lineage-specific manner. Nevertheless, we
were able to resolve differences in expression of known Oct4-
dependent genes. For example, we observed significantly lower
levels in Oct4 null embryos of Fgf4 at E3.75 and Spp1 at E3.75
and E4.5, consistent with prior reports (Botquin et al., 1998;
Nichols et al., 1998). Unexpectedly, Gata6 was significantly up-
regulated at E2.5 and Nanog was significantly upregulated at
E3.75 (Figure 6B), although no difference in Gata6 or Nanog
protein levels had been apparent by immunofluorescence in
Oct4 null embryos during preimplantation. Curiously, Gata6
levels did not significantly differ in Oct4 null blastocysts, even
though differences in Gata6 protein had been apparent. It is
interesting to consider the possibility that Gata6 could be post-
transcriptionally or posttranslationally regulated in the
blastocyst.
We next asked what proportion of the Oct4-dependent genes
might be directly transcriptionally regulated by Oct4. Because
the number of EPI and PE cells is too limited to perform Oct4
chromatin immunoprecipitation sequencing (ChIP-seq) with
blastocysts, stem cell models of pluripotent and PE-like cells
have been examined. Oct4 binding sites have been identified
in pluripotent F9 embryonal carcinoma (EC) cells and in F9 EC
cells that have been differentiated to PE-like cells by treatment
with retinoic acid (RA) (Aksoy et al., 2013). We examined inter-
secting sets of genes bound byOct4 in untreated andRA-treated
F9 cells (Aksoy et al., 2013) with our sets of genes that are Oct4
dependent in vivo (Table S1). This analysis indicated that around
18% of theOct4-dependent genes identified at E3.75 are bound
by Oct4 in EC cells before and/or after differentiation to PE-like
cells (Figure 6C). Notably, Oct4 binding sites were highly en-
riched near several important PE genes, including Pdgfra,
Gata4, and Gata6, in PE-like cells but not in untreated EC cells
(Figure 6D), consistent with a role for Oct4 in promoting PE
gene expression cell-autonomously. Oct4 binding sites were
also detected near other Oct4-dependent genes associated
with PE differentiation, such as Tdgf1 and Bmp4 (Kruithof-de Ju-
lio et al., 2011; Paca et al., 2012; Plusa et al., 2008) (Figure 6B and
data not shown), consistent with Oct4 regulating multiple PE
pathways in parallel.DevelWe next used the RNA-seq data to obtain a global view of how
Oct4 regulates blastocyst formation. We first performed gene
signature analysis to determine how EPI, PE, and TE gene signa-
tures (Table S1) are affected by loss of Oct4. Gene signature
analysis revealed that expression of genes associated with all
three lineages was progressively lost from Oct4 null embryos,
relative to wild-type, over the course of development (Figure 6E;
Figure S6). Curiously, PE and TE gene signatures were initially
weakly associated with Oct4 null embryos at E2.5, consistent
with the observed transient upregulation of Foxa2, Gata6, and
Eomes at the early time point (Figure 6B). However, the Oct4
null transcriptional profile was generally decreased at E4.5, rela-
tive to wild-type (Figure 6B), consistent with an overall develop-
mental failure of Oct4 null embryos rather than a conversion of
Oct4 null embryos to any one lineage.
We next focused on how Oct4 regulates pathways, rather
than individual genes, during preimplantation development.
We performed gene set enrichment analysis (GSEA) of func-
tional pathways (KEGG, Reactome, Biocarta) to identify path-
ways with significantly associated gene expression profiles in
Oct4 null or wild-type embryos and then visualized relation-
ships among the significant gene sets by generating enrich-
ment maps (Figures 6F–6H; Table S1). At E2.5, we failed to
identify any strong, concordant patterns of transcriptional dif-
ferences between wild-type and Oct4 null embryos. However,
at E3.75 and E4.25, multiple pathways were significantly dis-
rupted in Oct4 null embryos (Figures 6G and 6H). At E3.75,
the strongest patterns to emerge indicated a global failure of
Oct4 null embryos to upregulate oxidative phosphorylation,
glycolysis, and other metabolic pathways, with concomitant
aberrant upregulation of lipid metabolism and proteolytic path-
ways, especially those associated with promoting cell-cycle
progression and mRNA stability (Figures 6F and 6G). This trend
continued at E4.5 (Figure 6H), which could explain the
observed global decrease in transcription in Oct4 null embryos
by E4.5 (Figure 6B). In addition at E4.5, we observed an in-
crease in proteolytic pathways associated with DNA synthesis
in Oct4 null embryos (Figure 6H), consistent with stalled cell
proliferation. These results are also consistent with a failure to
activate known preimplantation energetic and metabolic tran-
scriptional programs (Leese, 2012) in the absence of Oct4,
leading to an energy-starved phenotype, manifested by the
misregulation of multiple basic cell biological processes and ul-
timately growth arrest. Consistent with this proposal, the initial
increase in protein translation pathways observed at E3.75 was
downregulated by E4.5. Interestingly, by E4.5 we observed a
weak but significant increase in the Yap/Taz pathway, a
pathway that promotes TE development (Nishioka et al.,
2009). Notably, several pathway genes contained Oct4 binding
sites in RA-treated F9 EC cells, including Itga3, Glud1, Eif4a2,
Anapc10, Hdac2, and Tead4 (Aksoy et al., 2013), which are
members of cytoskeletal regulation, amino acid metabolism,
protein translation, proteasome/cell-cycle regulation, tricarbox-
ylic acid cycle/oxidative phosphorylation, and Yap/Taz
pathway clusters, respectively (Figures 6G–6H; Table S1).
These observations suggest that Oct4 could regulate some
pathway members cell-autonomously. Taken together, our
RNA-seq analysis is consistent with a model in which Oct4 reg-
ulates expression of multiple EPI and PE genes as well asopmental Cell 25, 610–622, June 24, 2013 ª2013 Elsevier Inc. 617
AC
2
1
0
-1
-2
N
or
m
al
iz
ed
 
E
nr
ic
hm
en
t S
co
re WT
NULL
EPI
PE
TE
E2.5 E3.75 E4.5
*
* * * *
D
im
en
si
on
 2
150
100
50
0
-50
-100
-150
-1000 0 1000500-500
WT
NULL
NULL
NULL
WT
WT
E
2.
5
Dimension 1
NULL
NULL
NULL
WT
WT
WT
100
50
0
-50
-100
-150
-1000 1000-500 5000
E
3.
75
WT
WT
WT
NULL
NULL
NULL
200
100
0
-100
-200
-300
-1000 1000-500 5000
E
4.
5
D
Log2 (Oct4 null/wild type)
18
16
14
12
10
8
6
4
2
O
ct4-dependent
(612/6648 genes detected)
2.5-1.5 1.5-0.5 0.5-1.0 1.0 2.0-2.0 0-2.5
E3.75 18
16
14
12
10
8
6
4
2
2.5-1.5 1.5-0.5 0.5-1.0 1.0 2.0-2.0 0
O
ct4-dependent
(265/6545 genes detected)
-2.5
E4.5
Oct4
Oct4
18
16
14
12
10
8
6
4
2
2.5-2.5 -1.5 1.5-0.5 0.5-1.0 1.0 2.0-2.0 0
-L
og
10
 F
D
R
O
ct4-dependent
(472/7082 genes detected)
Oct4
Gata6
Lamb1
Pdgfra
Sox17
Sparc
Lama1
Lamc1
Spp1
Fgf4
Esrrb
Klf2
Bmp4
Tdgf1
Zscan10
Nanog
Gata4
Sparc
Lama1
Lamb1
Lamc1
Spp1
Tdgf1
Zscan10
E2.5B
Oct4-dependent genes (E3.75)
Oct4 pluripotency binding sites (F9)
Oct4 PE binding sites (F9 + RA)
Proteasome
Cell cycle 
regulation
mRNA stability
Lipid metabolism
Protein
translation
Mitosis
Amino acid 
metabolism
Energetic
metabolism
E3.75 E4.5
down in null
up in null
shared genes
TCA/Oxidative 
phosphorylation
Proteasome
Cell cycle 
regulation
mRNA stability
DNA synthesis
Protein
translation
Cytoskeleton 
regulation Glycolysis
Energetic
metabolism
Yap/Taz pathway
RTK signaling
G
TCA/Oxidative 
phosphorylation GlycolysisCytoskeleton 
regulation
GPCR
signaling
Eomes
772
47713 52
12171520
43
Foxa2
en
ric
he
d 
in
 w
ild
 ty
pe
en
ric
he
d 
in
 O
ct
4 
nu
ll
E F
control
Oct4 F9
Oct4 F9+RA
Sox17 F9+RA
control
Oct4 F9
Oct4 F9+RA
Sox17 F9+RA
control
Oct4 F9
Oct4 F9+RA
Sox17 F9+RA
sc
al
e:
 9
2
sc
al
e:
 5
7
sc
al
e:
 6
6
Pdgfra
Gata4
Gata6
chr5:75,530,000-75,552,000
chr14:63,848,961-63,885,658
chr18:11,000,000-11,060,000
H
(legend on next page)
Developmental Cell
Oct4 Promotes Endodermal Differentiation In Vivo
618 Developmental Cell 25, 610–622, June 24, 2013 ª2013 Elsevier Inc.
AB
 E2.5 E3.75 E4.5
w
ild
 ty
pe
O
ct
4 
nu
ll
TCA, Oxidative Phosphorylation, Glycolysis
Protein/Lipid/mRNA degradation 
TCA, Oxidative Phosphorylation, Glycolysis
DNA synthesis, transcription, translation
DNA synthesis, transcription, translation
EPI/PE/TE failing PE
EPI TE/EPI
PE failed PE
TE TE/failing PE
Nanog
Fgf4Gata6
Gata6 
EPI PE
Sox17
Pdgfra
Sox7
Mapk
Nanog
Cdx2
partial Gata4
late Gata6
Fgf4
Oct4
Oct4
E3.75-E4.5 (wild type)
Cdx2
Figure 7. Summary of Oct4 Null Phenotype
and Working Model
(A) In normal embryos, Oct4 promotes survival of
all three blastocyst lineages, facilitating trans-
cription of components of multiple metabolic
pathways as well as lineage-specific, cell-fate-
determining transcription factors.
(B) In EPI cells, Oct4 induces expression of multi-
ple genes, including signaling molecules such as
Fgf4 that induce PE cell fate non-cell-autono-
mously. In PE cells, Oct4 normally acts down-
stream of Mapk to promote expression of Sox17,
Pdgfra, Gata4, Sox7, and eventually Gata6. In
parallel, Mapk represses Nanog in an Oct4-
independent manner in PE cells. Also in parallel,
Oct4 represses expression of Cdx2 and other TE
genes in ICM cells.
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Oct4 Promotes Endodermal Differentiation In Vivopathways essential for the continued proliferation of the preim-
plantation embryo.
DISCUSSION
Our studies point to a cell-autonomous role for zygotic Oct4 in
PE development. Although Oct4 is often thought of as a pluripo-
tency factor, the idea thatOct4 has multiple developmental roles
is supported by precedent in the literature. First, Oct4 is detected
in both EPI and PE compartments of the blastocyst at equal
levels (Guo et al., 2010; Palmieri et al., 1994). Second, Oct4
orthologs are required for definitive endoderm development in
zebrafish (Onichtchouk, 2012). Third, Oct4 participates in endo-
derm formation in stem cell models (Aksoy et al., 2013; Gore
et al., 2011; Niwa et al., 2000; Stefanovic et al., 2009; Teo
et al., 2011; Zeineddine et al., 2006). Surprisingly, we did not
observe a requirement for m Oct4, in contrast with the reported
preimplantation knockdown phenotype (Foygel et al., 2008).
Rather, our data indicate that z Oct4 promotes expression of
multiple PE and pluripotency genes (Figures 7A and 7B).
Although Oct4 is required for expression of Nanog and Sox2 in
ES cells (Kuroda et al., 2005; Loh et al., 2006; Tomioka et al.,
2002), we found thatOct4 is not required for the initial expressionFigure 6. Oct4 Is Required for Expression of Markers of Multiple Linea
(A) MDS plots of Oct4 null (NULL) and wild-type (WT) individuals generated from
developmental stage (as indicated).
(B) Volcano plots for each stage highlighting key developmental genes (red) and
line; false discovery rate [FDR] < 0.05).
(C) Venn diagrams showing degree of overlap between E3.75Oct4-dependent ge
et al., 2013) (similar degrees of overlap were observed between the ChIP-seq da
(D) Examples of ChIP-seq data from Aksoy et al. (2013) showing locations of O
threshold set for the analysis shown in (C). For reference, control (immunoglobul
(E) Gene signature analysis showing enrichment scores for lineage-specific quer
each stage (*FDR < 0.05). Higher enrichment scores indicate higher relative leve
(F) Representative GSEA plots for major and minor networks shown in (G).
(G and H) Enrichment map networks generated from gene set enrichment analysi
direction of gene expression difference between the genotypes (as indicated). Gr
shared genes. GPCR, G-protein-coupled receptor; TCA, tricarboxylic acid cycle
See also Figure S6 and Table S1.
Develof these genes in the blastocyst. Thus genetic interactions in ES
cells may be maintenance rather than initiation phases of gene
regulation when compared to the blastocyst. We also showed
that Oct4 simultaneously promotes expression of multiple PE
genes. Knockout of Gata6, Gata4, Sox17, or Sox7 individually
does not disrupt PE development prior to implantation (Artus
et al., 2011; Kanai-Azuma et al., 2002; Koutsourakis et al.,
1999; Kuo et al., 1997; Molkentin et al., 1997; Wat et al., 2012),
consistent with genetic redundancy among PE transcription
factors, yet the Oct4 null phenotype is stronger than loss of
any one of these PE transcription factors. Accordingly, Sox17
is not required for initial expression of Pdgfra, Sox7, and Gata4
(Artus et al., 2011), and so loss of Sox17 alone cannot account
for loss of these genes in Oct4 null embryos. Thus, Oct4 regu-
lates multiple PE genes in parallel, possibly by direct transcrip-
tional activation.
Our data support a cell-autonomous role for Oct4 in PE devel-
opment, but our model does not rule out an additional role for
Oct4 in promoting PE development non-cell-autonomously.
Fgf4 is reduced in Oct4 null blastocysts, and we showed that
treatment with exogenous Fgf4/Hep or wild-type ES cells was
sometimes able to induce low levels of some PE genes in a
subset of cells, suggesting that Fgf4/Mapk signaling can actges and Metabolic Pathways
the top 500 genes, filtered for maximum variation between samples at each
proportion of significantly different, Oct4-dependent genes (above red dotted
nes and genes bound byOct4 in F9 cells and F9 treated with RA for 72 hr (Aksoy
ta sets and the E2.5 or E4.5 Oct4-dependent genes; not shown).
ct4 binding sites (boxed regions) near Pdgfra, Gata4, and Gata6 that exceed
in G ChIP) and Sox17 ChIP tracks are shown.
y signature gene sets evaluated against target gene signature distributions at
ls of lineage-specific gene expression (WT versus NULL).
s results. Nodes represent individual gene sets, and node color corresponds to
een lines indicate shared genes and line thickness is proportional to number of
.
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heterogeneously dependent on Oct4 for Fgf4-induced PE gene
expression. Heterogeneity among PE cells is known
(Takaoka et al., 2006), but it is not known whether Oct4 plays
different roles within PE populations. Ultimately, exogenous
Fgf4/Hep failed to rescue most PE gene expression and
outgrowth of PE cells from Oct4 null embryos, underscoring the
essential cell-autonomous role for Oct4 in PE cell development.
A remaining question is, what do Oct4 null PE cells become?
We find no evidence for increased apoptosis in Oct4 null
embryos, and our data indicate that Oct4 null PE cells do not
acquire EPI fate. We find that some, but not all,Oct4 null PE cells
acquire Cdx2 expression. However, all three lineages are devel-
opmentally compromised in Oct4 null embryos, which are defi-
cient in transcription of oxidative phosphorylation and glycolysis
pathways that are especially active in TE cells (Houghton, 2006;
Leese, 2012). These results point to stalled proliferation in Oct4
null embryos, and we did not observe an increase in PE differen-
tiation genes (Paca et al., 2012) in Oct4 null embryos by RNA-
seq. TE proliferation can be rescued in Oct4 null ICMs by
exogenous Fgf4 (Nichols et al., 1998), but it is not clear whether
all ICM cells are rescued by this treatment. Future work to
elucidate the developmental potential of Oct4 null ICM cells on
a cell-by-cell level will be particularly important, given the
requirement for Oct4 in repressing TE fate in ES cells (Niwa
et al., 2000) and our limited understanding of the cellular origin
of ES cells within the ICM.
Finally, our data suggest that Oct4 activity is regulated in a cell-
type-dependent manner to cell-autonomously regulate expres-
sion of EPI or PE pathways. Several mechanisms could regulate
cell-type-dependent Oct4 activity. First, Oct4 activity could be
regulated by phosphorylation. In support of this model, our
data show that Oct4 acts downstream of Mapk, and Mapk-
dependent Oct4 phosphorylation has been observed in human
ES cells (Brumbaugh et al., 2012). Moreover, phosphorylation
of Oct4 can alter its transcriptional activity in mouse ES cells
(Saxe et al., 2009). Whether Oct4 phosphorylation contributes
to lineage specification in the blastocyst is not known. Second,
Oct4 nuclear export dynamics differ between presumptive EPI
and PE populations (Plachta et al., 2011) and could regulate
Oct4 activity in a cell-type-dependent manner. However, the
mechanisms regulating Oct4 import/export and the functional
importance of these differences are unresolved. Finally, Oct4
transcriptional activity could be regulated by cell-type-specific
cofactors. For example, Oct4 could partner with Sox2 in EPI cells
and with Sox17 or Sox7 in PE cells. Notably, Oct4 can bind to
Sox17 in vitro, and this changes the Oct4 DNA binding pattern
(Aksoyet al., 2013; Jauchet al., 2011;Nget al., 2012).Weshowed
here that Sox17 expression is itself dependent onOct4, suggest-
ing that Sox17 participates in a PE-specific feed-forward mech-
anism to reinforce PE cell fate in the blastocyst. Addressing these
models will provide exciting new insight into an important stem
cell factor and the establishment of cell lineages in the blastocyst.EXPERIMENTAL PROCEDURES
Mouse Strains and Genotyping
The following alleles or transgenes were maintained in an outbred (CD1) back-
ground: Pou5f1tm1Scho (Kehler et al., 2004) and Tg(Zp3-cre)93Knw (de Vries620 Developmental Cell 25, 610–622, June 24, 2013 ª2013 Elsevier Iet al., 2000). Mice heterozygous for the Pou5f1 deletion allele (Oct4del+) were
generated by crossing mice carrying Pou5f1tm1Scho with 129-Alpltm1(cre)Nagy
(Lomelı´ et al., 2000). Mice were genotyped from ear punches (primer
sequences are provided in the Supplemental Experimental Procedures). All
animal research was conducted in accordance with the guidelines of the
University of California Santa Cruz Institutional Animal Care and Use
Committee.
Embryo Collection and Culture
Miceweremaintained on a 12 hr light/dark cycle. Embryoswere collected from
timed natural matings by flushing dissected oviducts or uteri with M2medium.
Embryos were either fixed or cultured in KSOM (Millipore) at 37C and 6%
CO2. Embryos were cultured in 1 mg/ml Fgf4 recombinant human Fgf4 (R&D
Systems) and 1 U/ml heparin (Sigma). For outgrowth assays, embryos were
cultured as above until E4.5 and then transferred to individual wells of MEF-
conditioned TSmedium (Tanaka et al., 1998) with 1 mg/ml each Fgf4/Hep. Final
concentrations of Fgfr/Mapk inhibitors were 100 nM PD173074 and 500 nM
PD0325901 (Stemgent).
Immunofluorescence and Confocal Microscopy
Embryos were fixed, stained, imaged, and recovered for genotyping as
previously described (Ralston and Rossant, 2008). Optical sections 5 mm in
thickness were collected as previously described (Blij et al., 2012). Antibody
information is given in Supplemental Experimental Procedures.
Embryo and ES Cell Aggregation
YFP-expressing R1 ES cells (George et al., 2007) were cultured on MEFs in ES
cell medium + 1 mM PD0325901 + 3 mM GSK3 inhibitor Chir99021 (Stemgent)
(Nichols et al., 2009). Precompacted four- to eight-cell embryos were collected
from Oct4fl/del intercrosses, zonas pellucida removed with Tyrode’s solution,
and embryos aggregated with groups of three to five ES cells in depression
wells. Aggregations were cultured in KSOM under light mineral oil at 37C
and 6% CO2. Chimeras were subsequently genotyped by PCR using primers
that could distinguish wild-type, floxed, and deleted Oct4 alleles (see Supple-
mental Experimental Procedures).
RNA Isolation and cDNA Preparation
Embryos were collected from natural timed matings and transferred to 50 ml
Picopure extraction buffer (Acturus Biosciences). RNA isolation was carried
out according to the manufacturer’s instructions. Single-blastocyst qPCR
was performed as previously described (Blij et al., 2012). For each embryo
examined, approximately 1 kb transcripts were selectively amplified from
the 30 ends to produce four independent complementary DNA libraries, which
were then pooled prior to sequencing (Kurimoto et al., 2007). Sequencing was
performed on an Applied Biosystems SOLiD4 sequencing platform. Read
depth for each embryo is provided in Table S1.
Analysis of RNA Sequence Data
Detailed procedures for statistical analysis of RNA-seq data, gene signature
analysis, GSEA, pathway analysis, enrichment map analysis, and ChIP-seq
analysis are provided in Supplemental Experimental Procedures.
ACCESSION NUMBERS
The GEO accession number for the RNA sequence reported in this paper is
GSE47089.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.devcel.2013.05.004.
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